top of page

END Childhood TB

The Evaluation of Novel Diagnostics for Childhood Tuberculosis (END Childhood TB) study is a five year study funded by the U.S. National Institutes of Health to evaluate novel point-of-care tests and identify biomarkers for diagnosis of TB in children. The study will enroll 875 children with presumed TB, collect samples for conventional and novel TB tests, and follow children for up to 6 months to assess outcomes. A comparison group of 100 healthy children and children with other respiratory illnesses will also be enrolled. Enrollment began in November 2018. Biomarkers and tests being evaluated include breath volatile organic compounds, novel stool processing methods for Xpert MTB/RIF Ultra testing, cell-free DNA in blood and urine samples, and novel urine LAM assays.

For more information, see our publications page


END Childhood TB Team Members

Principal Investigators: Adithya Cattamanchi, Eric Wobudeya

Co-Investigators: Alfred Andama, Moorine Sekadde, Devan Jaganath

Collaborators: Swomitra Mohanty, Niaz Banaei

Coordinator: Peter Wambi

Data Analyst: Rebecca Crowder

Study Nurse Coordinator: Jascent Nakafeero

Study Nurses: Emma Kiconco, Gertrude Nanyonga

Laboratory Technologist: Moses Nsereko, Ernest Oumo Aben

Study Runner: Sam Wailagala

Procedure Nurses: Annet Nambalirwa, Beatrice Kisembo Asaba

bottom of page